DDBasic Materials · Specialty ChemicalsThe 18 Wall Street analysts covering DuPont de Nemours, Inc. hold a median 12-month price target of $163 — +20.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 22 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DuPont de Nemours, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (100): The share count has been shrinking and the company is not leaning on new borrowing.
Growth (28): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (10): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on DD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +20.7% from it.
Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | RBC Capital | Maintains | Outperform | $176 → $160 |
| 13 Oct 2026 | Barclays | Initiates | Overweight | $156 |
| 9 Oct 2026 | JP Morgan | Downgrade | Neutral | $172 → $145 |
| 7 Oct 2026 | Citigroup | Maintains | Buy | $170 → $162 |
| 7 Oct 2026 | Citigroup | Maintains | Buy | — |
| 5 Oct 2026 | UBS | Maintains | Buy | $178 → $172 |
| 5 Oct 2026 | UBS | Maintains | Buy | — |
| 10 Aug 2026 | JP Morgan | Maintains | Overweight | — |
| 10 Aug 2026 | JP Morgan | Maintains | Overweight | $171 → $172 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $180 → $176 |
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 5 Aug 2026 | UBS | Maintains | Buy | — |
| 5 Aug 2026 | UBS | Maintains | Buy | $175 → $178 |
| 2 July 2026 | Citigroup | Maintains | Buy | — |
| 2 July 2026 | Citigroup | Maintains | Buy | $168 → $170 |
| 23 June 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 11 May 2026 | RBC Capital | Maintains | Outperform | — |
| 6 May 2026 | UBS | Maintains | Buy | — |
| 24 Apr 2026 | RBC Capital | Maintains | Outperform | — |
| 21 Apr 2026 | B of A Securities | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DD appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 22 Oct 2026, DuPont de Nemours, Inc. returned +36.2% against +15.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 21% of US stocks
Cheaper than 44% of US stocks
Cheaper than 60% of US stocks
Cheaper than 29% of US stocks
Higher than 36% of US stocks
Higher than 87% of US stocks
Higher than 42% of US stocks
Higher than 71% of US stocks
Higher than 49% of US stocks
Higher than 47% of US stocks
Higher than 59% of US stocks
Higher than 77% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DuPont de Nemours, Inc. has a market value of $18.1B and an enterprise value of $19.7B.
Revenue in the twelve months to 30 June 2026: $4.7B. The latest quarter grew 4.0% year on year.
Net income over the same four quarters: $84.0M, a 1.8% net margin.
Diluted earnings per share, trailing twelve months: $0.45.
Free cash flow in the twelve months to 30 June 2026: $647.0M, after $339.0M of capital spending.
DuPont de Nemours, Inc. spent $417.0M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 36.1×; forward P/E: 16.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.79%, paying out 81% of earnings.
DuPont de Nemours, Inc. employs 15,000 people — $313K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DuPont de Nemours, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DuPont expanded its bioprocessing portfolio with AmberChrom SIL silica gel, intended for high-purity peptide purification amid growing demand for GLP-1 therapeutics.
Why it matters — The product expansion connects DD's bioprocessing offerings with demand for peptide purification in GLP-1 therapeutics.
DuPont announced AmberChrom™ SIL, a new reverse-phase silica-based chromatography medium designed to support purification and manufacturing of peptide therapeutics, including GLP-1 receptor agonists. The company says it supports demanding purity targets and integrated workflows from crude purification through final polishing.
Why it matters — The launch adds a product aimed at biopharmaceutical manufacturers producing peptide therapeutics, including GLP-1 medicines.
A 24/7 Wall Street article says six industrial companies are selling off divisions while maintaining high dividend payouts, but argues that cash-flow figures complicate the attractive headline yields. The excerpt does not identify DuPont specifically.
Why it matters — DD watchers may find the article’s focus on dividend coverage and cash flow relevant, though the excerpt provides no DD-specific details.
DuPont’s innovation investments, healthcare acquisitions and productivity gains are supporting growth, and the company raised its 2026 earnings guidance despite persistent cost pressures.
Why it matters — DD watchers may note the combination of growth initiatives and improved earnings guidance alongside ongoing cost pressures.
DuPont’s Board declared a regular quarterly dividend of $0.60 per share on its common stock. It is payable December 15, 2026, to shareholders of record at the close of business on November 30, 2026.
Why it matters — DD watchers may note the declared dividend amount and the payment and record dates.
The 18 Wall Street analysts covering DuPont de Nemours, Inc. have a median 12-month price target of $163, with estimates ranging from $145 to $186. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 18 analysts covering DuPont de Nemours, Inc., 14 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DuPont de Nemours, Inc. 83 out of 100 across roughly 4,600 US stocks as at 22 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Oct 2026, DuPont de Nemours, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (100 of 100).
No one can know that. What the data says: the median 12-month target from 18 analysts implies +20.7% from the last close, and Ticker Nerd's factor model ranks DuPont de Nemours, Inc. 83 out of 100 as at 22 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DuPont de Nemours, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $145 to $186 over the next 12 months.
DuPont de Nemours, Inc. returned +36.2% over the 12 months to 22 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
DuPont de Nemours, Inc. is a global advanced materials and specialty solutions company focused on serving industrial and technology-driven markets.
The most recent item we track (Zacks Investment Research, 23 Oct 2026): "DuPont Expands Bioprocessing Portfolio With New Chromatography Media". DuPont expanded its bioprocessing portfolio with AmberChrom SIL silica gel, intended for high-purity peptide purification amid growing demand for GLP-1 therapeutics.
DuPont de Nemours, Inc. is a global advanced materials and specialty solutions company focused on serving industrial and technology-driven markets. DuPont develops and supplies materials used in electronics manufacturing, semiconductor fabrication, advanced packaging, water filtration, construction, transportation, healthcare, and worker safety. Its current product portfolio includes semiconductor materials, adhesives, resins, laminates, industrial films, medical packaging, filtration technologies, and protective materials designed for demanding technical applications. The company works primarily with business and institutional customers that rely on high-performance materials to support production, reliability, and process efficiency across complex supply chains. Headquartered in Wilmington, Delaware, DuPont plays an important role in the materials sector by providing solutions that connect scientific innovation with essential end markets in electronics, water, healthcare, and industrial manufacturing.
CEO Ms. Lori D. Koch · 15,000 employees · United States · https://www.dupont.com
